Stocks of Viatris Inc (NASDAQ:VTRS) traded higher last session on Wall Street, down -0.31% to $9.66.
According to the data, Viatris Inc (NASDAQ:VTRS) has 12 analysts covering its stock. The consensus rating among analysts is ‘Hold’. As we calculate the median target price by taking the range between a high of $15.00 and a low of $10.00, we find $12.95. Given the previous closing price of $9.69, this indicates a potential upside of 33.64 percent. VTRS stock price is now -7.41% away from the 50-day moving average and -6.82% away from the 200-day moving average. The market capitalization of the company currently stands at $11.59B.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
A total of 7 analysts have issued a hold rating and 3 have given it a buy rating. Brokers who have rated the stock have averaged $12.61 as their price target over the next twelve months.
With the price target maintained at $11, Barclays recently Downgraded its rating from Equal Weight to Underweight for Viatris Inc (NASDAQ: VTRS).
In other news, Ni Xiangyang (Sean), President, Greater China sold 3,148 shares of the company’s stock on Mar 06. The stock was sold for $34,891 at an average price of $11.08. Upon completion of the transaction, the President, Greater China now directly owns 46,416 shares in the company, valued at $0.45 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Mar 03, President, Greater China Ni Xiangyang (Sean) sold 3,093 shares of the business’s stock. A total of $34,579 was realized by selling the stock at an average price of $11.18. This leaves the insider owning 41,729 shares of the company worth $0.4 million. Insiders disposed of 660,775 shares of company stock worth roughly $6.38 million over the past 1 year. A total of 1.82% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in VTRS stock. A new stake in Viatris Inc shares was purchased by RUBRIC CAPITAL MANAGEMENT LP during the first quarter worth $115,437,000. SLATE PATH CAPITAL LP invested $75,551,000 in shares of VTRS during the first quarter. In the first quarter, POINT72 ASSET MANAGEMENT, L.P. acquired a new stake in Viatris Inc valued at approximately $31,609,000. WOODLINE PARTNERS LP acquired a new stake in VTRS for approximately $7,849,000. M&G INVESTMENT MANAGEMENT LTD purchased a new stake in VTRS valued at around $7,429,000 in the second quarter.
Friday’s opening bell rang with an opening price of $9.66 for Viatris Inc (NASDAQ: VTRS). During the past 12 months, Viatris Inc has had a low of $8.67 and a high of $12.40. As of last week, the company has a debt-to-equity ratio of 0.90, a current ratio of 1.50, and a quick ratio of 0.94. The fifty day moving average price for VTRS is $10.42 and a two-hundred day moving average price translates $10.36 for the stock.
The latest earnings results from Viatris Inc (NASDAQ: VTRS) was released for Jun, 2023. According to the Drug Manufacturers – Specialty & Generic Company, earnings per share came in at $0.75, beating analysts’ expectations of $0.71 by 0.04. This compares to $0.26 EPS in the same period last year. The net profit margin was 11.93% and return on equity was 9.12% for VTRS. The company reported revenue of $3.92 billion for the quarter, compared to $4.12 billion a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -4.81 percent. For the current quarter, analysts expect VTRS to generate $4.02B in revenue.
Moreover, the firm recently paid out its quarterly dividend on 09/15/2023. Investors who held shares on 08/24/2023 were paid a $0.12 dividend. On an annualized basis, this represents a $0.48 dividend and a 4.97% percent yield. There was an ex-dividend date of 08/23/2023 for this dividend. In terms of dividend payout ratio, VTRS is presently at 28.11%.
Viatris Inc(VTRS) Company Profile
Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It provides its medicines in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. The company distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. It sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, and Yupelri; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; and Celebrex and ARV names, as well as glargine and SEMGLEE names. The company has collaboration and licensing agreements with Revance Therapeutics, Inc.; Momenta Pharmaceuticals, Inc.; Theravance Biopharma, Inc.; and Fujifilm Kyowa Kirin Biologics Co. Ltd. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.
